valu usd unless otherwis note
back in-lin trim estim pt
view believ turnaround pharmedium unit could
extend given involv doj earn
result overst vs peer opioid cost exclus like limit
opportun share price out-performance
get cautiou reduc price target
share lower ep reflect cautiou view
challeng pharmedium adjust estim
peer comparison purpos includ opioid litig expens
compar basi reduc ep estim due
lower pharmedium forecast low end guidanc
 well street howev new
forecast also reflect impact opioid litig expect
recur expens believ includ non-gaap
ep inclus forecast expens new
ep estim
pharmedium challeng believ challeng pharmedium
could persist longer street expect consult check
indic memphi facil could offlin
given inclus doj review addit fda review
would put ep low end compani guidanc believ
doj involv indic escal issu fda
unabl settl issu pharmedium believ
doj could push consent decre would expect consent decre
slow restart memphi facil believ increas
risk pharmedium facil see disrupt ad expens
opioid expens current exclud opioid litig expens
drug distributor includ part non-gaap
earn estim incur opioid litig
expens includ ep impact
estim impact earn believ legal
expens on-going includ earn estim
maintain sector perform maintain sector perform rate
lower price target price target base
unchang multipl appli ep estim
execut remain strong asid pharmedium
earn appear state see neg revis risk street
number addit exposur harder quantifi risk
like medicar part brand drug price risk
dissemin produc price prior trade day market close estimate unless otherwis note
believ share like multipl rang bound
investor get visibl gener drug price
bottom oper earn growth resum
pressur last
month multipl issu relat drug price
weigh result expect backdrop
improv next month howev believ
best-posit wholesal
meet earn target given conserv guidanc
relationship walgreen though note
rel strength seem reflect current share
estim gener profit
core us drug distribut busi sale gener
drug past two year seen
price gener drug deflat high-single-digit mid-
teen percentag rate profit dollar contribut
fall slightli lower rate gener deflat continu
high-single-digit pace higher believ
volum growth abl
grow earn segment though may best
posit creat spread price fall
upsid risk sector perform rate share
includ stabil drug price environ
could caus earn estim stabil like drive
multipl expans close market multipl
downsid risk sector perform rate includ
acceler drug price deterior gener
market potenti client loss wholesal
sell-sid price compress larger pharmaci
custom gpo
bloomberg capit market estim upside/downside/target
price target share equal
ep estim use multipl reflect
slight discount averag forward trade
multipl share due uncertainti surround
upsid scenario share base
ep estim higher base case price-to-earnings
multipl appli ep scenario upsid scenario
ep better ep growth could
driven success partnership walgreen increas
volum across brand gener drug success capit
deploy level gener price deflat
forward multipl repres high end
normal trade rang drug wholes space
multipl like get neg
downsid scenario share base
ep estim base case price-to-earnings multipl
appli ep scenario downsid scenario
ep lower-than-expect ep could
driven worse-than-expect price environ
lower-than-expect brand gener volum lack
avail opportun forward multipl
like get posit share
lower estim reflect cautiou forecast pharmedium
includ zero contribut memphi facil limit profit contribut
pharmedium facil put forecast low end guidanc
well street forecast addit includ
litig expens relat opioid model forecast million litig
expens believ includ report non-gaap expens
view litig expens recur expens forecast continu
also believ includ litig expens make report ep
compar drug distribut peer includ opioid relat litig expens
report ep
exhibit put take adjust opioid litig expens
exhibit compar drug distributor valuat normal opioid litig expens
amerisourc put put takescor busi brand price limit growthhd smith year benefitpharmedium memphi plant assum restartlap dist center segment growthful year acquir rampshar share count reductiontot rel estim ex opioidsinclus opioid litig expensea headwind guid adjust growthyoy healthcar technolog distribut
price target share support sector perform rate equal
ep estim use multipl reflect slight discount
averag forward trade multipl share due uncertainti surround
risk rate price target
forese upsid downsid risk sector perform rate share
upsid risk includ stabil drug price environ could caus earn
estim stabil like drive multipl expans close market multipl
downsid risk includ acceler drug price deterior gener market
potenti client loss wholesal sell-sid price compress
larger pharmaci custom gpo
pharmaceut distribut consult compani oper
distribut segment
distribut segment includ amerisourcebergen drug corpor abdc
compani amerisourcebergen consult servic abc world courier mwi
veterinari suppli busi partnership walgreen boot
allianc global drug sourc distribut product locat
good sold
segment revenu
segment revenu
amort intang
revenu
segment revenu
segment revenu
incom discontinu oper net tax
net loss attribut non-controlling interest
net incom attribut
earn per share continu oper
weight average number share
